Synthesis, X-ray Crystal Structure and Antimicrobial activity of unexpected trinuclear Cu(II) complex from *s*triazine-Based Di-compartmental Ligand *via* selfassembly

| Saied M. Soliman*, Jamal Lasri ^ь , Matti Haukka, Essam N. Sholkamy, Hessa H. Al- | | | | | | | | |
|---|---|--|--|--|--|--|--|--|
| Rasheed ^e , Ayman El-Faham [*] | | | | | | | | |
| Table of Content | | | | | | | | |
| S1 | X-ray Structure Determination | | | | | | | |
| Figure S1 | Growth inhibition images of target pathogenic microbes with the Cu(II) complex (1) and H ₂ L (2), negative control DMSO alone (C), positive control, Gentamicin | | | | | | | |
| Figure S2 | Photography images of inhibition of pathogenic microbe's growth at different concentrations of synthetic compounds to determine their MIC and MBC; the Cu(II) complex (1) and H ₂ L (2). | | | | | | | |
| Table S1 | AIM Topological parameters (a.u.) of the Cu-N, Cu-Cl and Cu-O interactions. | | | | | | | |

S1- X-ray Structure Determination

The crystal of $[Cu_3(HL)(Cl)_2(NO_3)(H_2O)_5](NO_3)_2$ (1) was immersed in cryo-oil, mounted in a MiTeGen loop and measured at 120 K on a Rigaku Oxford Diffraction Supernova diffractometer using Mo K α (λ = 0.71073 Å) radiation. The CrysAlisPro [16] program package was used for cell refinement and data reduction. Multi-scan absorption correction (*CrysAlisPro* [16]) was applied to the intensities before structure solution. The structure was solved by intrinsic phasing method using the *SHELXT* [17] software. Structural refinement was carried out using *SHELXL-2017* [17] program and *Olex2* [18] graphical user interface. The NH hydrogen atom was located from the difference Fourier map and refined isotropically. The H₂O hydrogen atoms were also located from the difference Fourier map but constrained to ride on their parent oxygen with U~iso~ = 1.5 U~eq~(parent atom). Other hydrogen atoms were positioned geometrically and constrained to ride on their parent atoms, with C-H = 0.95-0.98 Å and U_{iso} = 1.2-1.5 U_{eq} (parent atom). The crystallographic details are summarized in Table **1**. **Figure S1** Growth inhibition images of target pathogenic microbes with the Cu(II) complex (1) and H₂L (2), negative control DMSO alone (C), positive control, Gentamicin.



Figure S2 Photography images of inhibition of pathogenic microbe's growth at different concentrations of synthetic compounds to determine their MIC and MBC; the Cu(II) complex (1) and H₂L (2).



| Bond | Q(r) | G(r) | V(r) | H(r) | V(r)/G(r) | Eint ^a | | |
|-----------|--------|--------|---------|---------|-----------|-------------------|--|--|
| Cu1-Cl1 | 0.0773 | 0.0745 | -0.0979 | -0.0234 | 1.31 | 30.70 | | |
| Cu1-O1 | 0.0373 | 0.0469 | -0.0476 | -0.0008 | 1.02 | 14.95 | | |
| Cu1-N1 | 0.0789 | 0.0989 | -0.1194 | -0.0205 | 1.21 | 37.46 | | |
| Cu1-N2 | 0.0927 | 0.1310 | -0.1582 | -0.0272 | 1.21 | 49.64 | | |
| Cu1-N6 | 0.0739 | 0.0917 | -0.1096 | -0.0179 | 1.20 | 34.37 | | |
| Cu2-Cl2 | 0.0774 | 0.0822 | -0.1058 | -0.0236 | 1.29 | 33.20 | | |
| Cu2-O3 | 0.0317 | 0.0369 | -0.0366 | 0.0003 | 0.99 | 11.49 | | |
| Cu2-N9 | 0.0863 | 0.1087 | -0.1333 | -0.0246 | 1.23 | 41.82 | | |
| Cu2-N8 | 0.0954 | 0.1264 | -0.1563 | -0.0299 | 1.24 | 49.04 | | |
| Cu2-N4 | 0.0785 | 0.1029 | -0.1229 | -0.0200 | 1.19 | 38.56 | | |
| Cu3-N7 | 0.0841 | 0.1106 | -0.1337 | -0.0231 | 1.21 | 41.95 | | |
| Cu3-07 | 0.0398 | 0.0470 | -0.0492 | -0.0022 | 1.05 | 15.42 | | |
| Cu3-O6 | 0.0804 | 0.1234 | -0.1424 | -0.0190 | 1.15 | 44.67 | | |
| Cu3-O5 | 0.0796 | 0.1302 | -0.1478 | -0.0176 | 1.13 | 46.38 | | |
| Cu3-O4 | 0.0858 | 0.1247 | -0.1466 | -0.0219 | 1.18 | 45.99 | | |
| ªkcal/mol | | | | | | | | |

Table S1 AIM Topological parameters (a.u.) of the Cu-N, Cu-Cl and Cu-O interactions.